Talniflumate

Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase[1]. Talniflumate is an orally active Ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome[2].

Product Specifications

CAS Number

[66898-62-2]

Product Name Alternative

BA 7602-06

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Chloride Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/talniflumate.html

Purity

99.67

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)OC3OC(C4=C3C=CC=C4)=O

Molecular Formula

C21H13F3N2O4

Molecular Weight

414.33

Precautions

H302, H315, H319

References & Citations

[1]Hyun-Ji Kim, et al. Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man. Archives of Pharmacal Research volume 19, Article number: 297 (1996) |[2]Mollereau, et al. Agonist and Antagonist Activities on Human NPFF (2) Receptors of the NPY Ligands GR231118 and BIBP3226. Br J Pharmacol.2001 May;133 (1) :1-4.